Pune-based Serum Institute of India (SII) is prepared to increase production of injectable poliomyelitis vaccine (IPV) to fill the gap left by France s Sanofi closing its manufacturing plants in India. SII currently supplies half of the 20 million IPV doses to the government s immunization program and can provide additional doses with a 3-4 month notice. Adar Poonawalla, SII CEO, stated that supplying IPV to the government at current prices is unviable for most companies, but SII continues to do so as a service to the nation.